Colorado State University Develops Tuberculosis Vaccine
A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB).
A Colorado State University (Fort Collins, CO, www.colostate.edu) research team has developed a novel vaccine to prevent tuberculosis (TB). The vaccine triggers the body’s immunity in a novel way by activating specific immune system functions that enhance the response to the bacterium that causes tuberculosis. Although in preliminary stages of testing, the vaccine would likely be effective against all strains of TB, including multidrug and extensively drug-resistant tuberculosis. Preliminary evidence shows that the vaccine has promise of working after exposure to TB, which no other vaccine in current development has achieved. The vaccine is designed to be relatively easy to produce. Human trials for the vaccine could occur in two to three years.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
